Alnylam, Bayer, Boehringer Ingelheim, and Novo Nordisk will collaborate with PRECISE to analyze whole-genome and other data on 100,000 Singaporeans.

The study will test the combination, which aims to boost CD19 expression to make CAR T-cell therapy more effective, in patients with solid tumors.

The partners will also leverage AI tools and proprietary evaluation models to home in on targetable shared cancer antigens and develop vaccines against them.

Tessera will receive $150 million in upfront cash and equity investment from Regeneron and be eligible for up to $125 million in milestone payments.

The nonprofit is focused on access to precision medicine testing and treatment for former Special Operations Forces personnel ...

With $1.6 million from CPRIT, investigators are testing an endogenous T-cell therapy that has certain advantages over CAR ...

Doctors can use the test, developed by Endeavor Health in collaboration with GenomicMD, to direct more aggressive treatment ...

NEW YORK – The UK's National Institute for Health and Care Excellence has recommended Aucatzyl (obecabtagene autoleucel), a CAR T-cell therapy developed by Autolus Therapeutics, for routine use within ...

This article has been updated to reflect EU label data on the sustained clinical benefit of Breyanzi. NEW YORK – The European Commission on Monday approved Bristol Myers Squibb's CAR T-cell therapy ...

NEW YORK – The National Society of Genetic Counselors last week re-introduced a bill that would allow its members to bill Medicare. US Reps. Adrian Smith, R-Neb., and Kathy Castor, D-Fla., introduced ...